Flow Cytometry

December 2018 - Vol.7 No. 10 - Page #6

The promise of next-generation flow cytometry platforms including mass cytometry (CyTOF) and mass spectrometry-based digital imaging is substantial. With widespread use in immunophenotyping, analysis of hematopoietic neoplasias, diagnosis of primary immunodeficiencies, and for antibody screening and crossmatching, among other applications, flow cytometry is expected to continue to expand its clinical utility and utilization in clinical laboratories.


Utilization of flow cytometry has remained quite consistent over the past 5 years with just over 2 out of every 10 facilities taking advantage of this technology.

While rarely utilized in facilities with fewer than 200 beds, flow cytometry is a majority practice in the largest facilities with 400+ beds

BD and Beckman Coulter are the leading vendors in the flow cytometry marketplace.

Click here to view a larger version of this Chart

Flow cytometry delivers strong satisfaction; 78% of users give high marks to their vendors.

While most new adoptions will be concentrated in 400+ bed facilities, midsized hospitals expect to enjoy increasing adoption rates in the coming years.

As more facilities look to incorporate flow cytometry, lab directors are typically reviewing at least 3 different vendors. BD, Beckman Coulter, Sysmex, and Luminex are enjoying the lion’s share of this attention.

Click here to view a larger version of this Chart



Like what you've read? Please log in or create a free account to enjoy more of what www.medlabmag.com has to offer.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

Just answer the following quick question for your chance to win:

To continue, you must either login or register: